Research paperMapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle☆
References (30)
- et al.
Mechanistic studies of amsacrine-resistant derivatives of DNA topoisomerase II—Implications in resistance to multiple antitumour drugs targeting the enzyme
J Biol Chem
(1994) - et al.
Different modes of anthracycline interaction with topoisomerase II: Separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drug resistance
Biochem Pharmacol
(1993) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
Anal Biochem
(1976)- et al.
H2O2 as a DNA fragmenting agent in the alkaline elution interstrand crosslinking and DNA-protein crosslinking assays
Analyt Biochem
(1988) - et al.
Characterization of an amsacrine-resistant line of human leukemia cells
J Biol Chem
(1989) - et al.
Mode of action of topoisomerase-II-targeting agents at a specific DNA sequence. Uncoupling the DNA binding, cleavage and religation events
J Mol Biol
(1992) - et al.
Antagonistic effect of the cardioprotector (+)-1, 2,-bis(3-5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16)
Biochem Pharmacol
(1993) - et al.
Inhibition of epipodophyllotoxin cytotoxicity by interference with topoisomerase-mediated DNA-cleavage
Biochem Pharmacol
(1985) - et al.
Role of DNA intercalation in the inhibition of purified mouse leukemia (L1210) DNA topoisomerase II by 9-aminoacridines
Biochem Pharmocol
(1987) - et al.
Radiotherapeutic enhancement by razoxane
Cancer Treat Rev
(1991)
DNA transport by a type II DNA topoisomerase: Evidence in favor of a two-gate mechanism
Cell
(1994)
DNA topoisomerases—essential enzymes and lethal targets
Annu Rev Pharmacol Toxicol
(1994)
Altered DNA topoisomerase II activity in Chinese hamster cells resistant to topoisomerase II inhibitors
Cancer Res
(1986)
Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26
Biochemistry
(1988)
Teniposide-resistant CEM cells, which express mutant DNA topoisomerase II alpha, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme
Cancer Res
(1993)
Cited by (0)
- ☆
The study was supported by the Danish Cancer Society, the E. Dunielsen and Wife Foundation, the Danish Cancer Research Foundation, the Georg and Ellen Bjwkner Foundation, the Soren and Helene Hempels Legacy, and the Nooo-Nordisk Foundation.
Copyright © 1996 Published by Elsevier Inc.